Investigators conducted a multicenter retrospective study across ten oncology centers in Israel to evaluate first-line nivolumab-relatlimab for adults with unresectable or metastatic melanoma. The report identifies the study as a chart-review series; it included 117 patients. The abstract specifies the multicenter and retrospective nature, and lists participating clinical sites in the author affiliations, but the provided excerpt does not include detailed inclusion or exclusion criteria, performance-status distribution, prior therapies (if any), or dosing regimens. The study team therefore confirms a real-world cohort drawn from routine clinical practice, but the available text does not allow reconstruction of the case ascertainment window, enrollment dates, or follow‑up intervals.
The design choice—multicenter retrospective review—permits broader patient heterogeneity than controlled clinical trials. That heterogeneity can increase external validity for everyday practice, though it also introduces potential biases (selection, information, and confounding) that the full methods would need to address. The source excerpt does not report how the investigators handled missing data, adjudicated radiographic progression, or defined lines of therapy beyond “first-line” administration of the dual checkpoint inhibitor.
The abstract lists primary and secondary endpoints used by the study team: overall survival (OS), progression-free survival (PFS), melanoma-specific survival (MSS), objective response rate (ORR), and safety. These endpoints align with standard outcome measures used to evaluate immune checkpoint blockade in advanced melanoma. The authors also state they explored predictors of outcome using multivariable analyses, indicating an attempt to adjust for potential confounders and to identify clinical or pathologic factors associated with efficacy or harm.
The excerpt does not provide the investigators’ detailed statistical plan. There is no information in the provided text about censoring rules, survival-estimate methods (Kaplan–Meier or otherwise), proportional-hazards assumptions, covariates included in multivariable models, or whether sensitivity analyses were performed. Nor does the abstract excerpt specify the timing or criteria for response assessment (for example, RECIST v1.1 versus immune-related response criteria). Those methodological details are essential to interpret outcome estimates and comparative context with randomized data; they were not reported in the available source text.
The abstract confirms that 117 patients were included in the analysis. Beyond that cohort count, the excerpt truncates mid-sentence and does not provide numerical results for OS, PFS, MSS, ORR, response durability, median follow-up duration, or subgroup estimates. The study team’s reported intention to explore predictors is documented, but which predictors reached statistical significance (if any), and their effect sizes, are not present in the available text.
Because the provided PubMed excerpt is incomplete, readers cannot determine the magnitude of benefit or harm observed in this real-world cohort compared with prior randomized trials of nivolumab alone or with other combinations. The absence of reported survival medians, hazard ratios, confidence intervals, and p-values in the excerpt prevents quantitative comparison and precludes assessment of statistical robustness.
Safety and tolerability are named endpoints in the abstract. Given the dual checkpoint inhibition mechanism—targeting PD-1 and LAG-3—immune-related adverse events are a prespecified concern, and safety reporting is an expected element of the full paper. The excerpt, however, does not include any safety data: there are no event rates, no grades of toxicity, no treatment discontinuation figures, and no attribution of adverse events to nivolumab-relatlimab versus other causes. The authors’ statement that they explored predictors of outcomes implies that baseline variables (clinical, laboratory, or pathologic) were considered in multivariable models, but the excerpt does not list which variables were tested or the results of those models.
Without the full text, clinicians and guideline developers cannot evaluate which patient subgroups derived the most benefit, which characteristics predicted progression or death, or whether particular factors (for example, BRAF status, ECOG performance status, or presence of brain metastases) were associated with different outcomes in this cohort. The source excerpt does not fill those gaps.
The provided PubMed abstract documents the study’s aims, setting, cohort size (117 patients), and endpoints, but it is truncated and omits the core numerical findings and granular methods. The following key items are not available in the excerpt and therefore remain unanswered: median follow-up, median OS or PFS, ORR and duration of response, rates and grades of immune-related adverse events, reasons for treatment discontinuation, covariates included in multivariable analyses, and the investigators’ conclusions or recommendations.
Readers should consult the full published article (Eur J Cancer; DOI: 10.1016/j.ejca.2026.117047) for complete results, tables, and methodological appendices. The abstract excerpt alone documents an important real-world effort—multicenter, national, and focused on first-line nivolumab-relatlimab—but does not provide the quantitative data necessary to change practice or to compare outcomes directly with randomized clinical-trial populations. The absence of those data in the excerpt is the principal limitation of the source text provided here.